0ND5 — H. Lundbeck A/S Class B

Deep-value: 0ND5 — H. Lundbeck A/S class B

Analysis of 28 August 2026. Reference price: DKK … (Nasdaq Copenhagen, HLUN-B.CO; last close 41.80 on 26.08.2026). All figures in DKK millions unless otherwise specified.

Issuer identification — read before any figure. 0ND5 is the LSIN (London Stock Exchange International) line of H. Lundbeck A/S class B shares, ISIN DK0061804770. It isn’t a separate company: it’s the tracker’s third entry for the same issuer, alongside HLUN_A (class A, DK0061804697) and HLUN_B. The LSIN line is illiquid and its quote lags — the tracker has a price of … for 0ND5, and … for HLUN_B, on the same date. The correct price for valuation is the Copenhagen one (…), not the LSIN one. Yahoo returns a stale price and zero financials for 0ND5.L — which is why today’s initially generated data pack came out completely empty. I regenerated it after adding the alias 0ND5 → HLUN-B.CO to deep_data_pack.py (the same collision class as 1318/3600/110990 already documented there).

Lundbeck is NOT an SEC-registered issuer — no CIK, no 20-F filing, no SEC-Filings\0ND5 folder. The primary source for everything below is the company’s own filings, downloaded and read in this session: the 2025 Annual Report (IFRS, audited by PwC, signed 4 February 2026), Corporate Announcement no. 782/2026 (FY2025), the 2025 Remuneration Report, and the H1 2026 Financial Report (Announcement no. 793/2026, 19 August 2026).

Executive summary

The thesis. Lundbeck is a Danish neuroscience pharmaceutical company generating, today, approximately DKK 4.8 billion of free cash flow to shareholders on a DKK 41.5 billion market cap — an 11.5% yield. This yield isn’t an accounting illusion: I rebuilt it line by line from the audited consolidated cash flow statement, and it’s independently corroborated by the company’s own guidance for net debt at end-2026. The market pays this price because it assumes the flow erodes permanently. At a 9% discount rate and … terminal growth, the DKK … price implies a compound decline in free cash flow of … per year, for ten years. The investment question isn’t whether the stock is cheap on today’s figures — it obviously is — but whether the implied …/year decline is too pessimistic or exactly right.

Why I think it’s too pessimistic, but not massively so. Three things support the flow: (1) Vyepti is growing … CER in H1 2026, from an already large base (DKK 2,865 million over six months), and is the fastest-growing anti-CGRP in the US, with 13.01% market share; (2) Rexulti is growing … CER and has compound-patent protection through 2032 in the US, so it isn’t the asset that’s declining; (3) debt has fallen from DKK 12,182 million (Dec. 2024) to DKK 7,382 million (June 2026), and interest is falling with it — net financial expense guidance dropped from ~300 to ~200 million during the year. Against: Abilify Maintena is losing exclusivity one by one in Canada, Australia and Europe; Trintellix loses its compound patent in the US on 17 June 2026, with pediatric exclusivity through 17 December 2026; R&D expense is climbing to DKK 5.6-5.9 billion in 2026 from 4,895 in 2025 and management explicitly says it will keep rising; and the weak dollar cuts ~4 percentage points off reported revenue growth and ~8 points off adjusted EBITDA growth.

Estimated value. Five triangulated models give a range of DKK 38.5 – 56.7 per share, with a center around DKK 47.8, i.e. a margin of safety of roughly … versus …. A Monte Carlo simulation over 20,000 scenarios, centered on the zero-growth-flow assumption, gives a median intrinsic value of DKK … and an …% probability the stock is undervalued — but that range only varies the DCF’s parameters, not the accounting framing, and the framing is the biggest source of uncertainty here (see the valuation chapter). The consensus of the 11 analysts tracked by Investing.com stands at a DKK 45.59 average target (high 65, low 34), i.e. … — below my center, but in the same zone.

Verdict. Moderate buy — a starting position, not a conviction position. The ~14% margin of safety at the triangulation’s center doesn’t justify a large position in a company where 68% of assets are intangible, tangible book value is negative (−10,496 million), and most of the equity depends on a single Phase III asset (bexicaserin, product right of DKK 16,453 million) with a pivotal readout due by end-2026. The argument for buying now, rather than waiting for the readout, is that the balance sheet is solid (net debt/EBITDA 1.0x, covenant at 4.0x), current flow covers the dividend more than four times over, and my DCF’s bear scenario — a …/year decline at a 9.5% rate — still gives DKK 38.52, i.e. only an 8% loss versus today’s price. The asymmetric risk is favorable; the magnitude isn’t spectacular.

Divergence from the tracker. The GBL score from 23.08.2026 is 20.25/30 = …%, i.e. “Interesting”. I agree with the level, but not with all the components: the tracker gives 1 point for an FCF yield of “~12.9%” without checking the bridge (the correct figure is 11.5% for 2025 and 12.2% on the trailing four quarters — so the conclusion holds, but by luck), notes “CEO since 2022” when the Annual Report says 2023, and gives 1/1 for skin in the game to a company whose CEO holds no shares at all. Details in the last chapter.